BSX VS JNJ Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividendSentiment
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilityDividendSentiment

Performance

BSX
100/100

BSX returned 26.68% in the last 12 months. Based on SPY's performance of -12.97%, its performance is above average giving it a score of 100 of 100.

JNJ
73/100

JNJ returned -15.84% in the last 12 months. Based on SPY's performance of -20.60%, its performance is above average giving it a score of 73 of 100.

Analyst Price Targets

BSX
79/100

24 analysts offer 12-month price targets for BSX. Together, they have an average target of 57.93, the most optimistic target put BSX at 132 within 12-months and the most pessimistic has BSX at 43.

JNJ
63/100

23 analysts offer 12-month price targets for JNJ. Together, they have an average target of 176.5, the most optimistic target put JNJ at 205 within 12-months and the most pessimistic has JNJ at 90.

Technicals

BSX
89/100

BSX receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

JNJ
14/100

JNJ receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

BSX
26/100

BSX has missed earnings 4 times in the last 20 quarters.

JNJ
100/100

JNJ has missed earnings 0 times in the last 20 quarters.

Profit

BSX
72/100

Out of the last 20 quarters, BSX has had 18 profitable quarters and has increased their profits year over year on 8 of them.

JNJ
74/100

Out of the last 20 quarters, JNJ has had 19 profitable quarters and has increased their profits year over year on 9 of them.

Volatility

BSX
48/100

BSX has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

JNJ
43/100

JNJ has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

Dividend

BSX
10/100

BSX's most recent dividend was $0.01 per share, based on a share price of $53.85. It was a payout ratio of -8.24% compared to their total earnings.

JNJ
100/100

JNJ's most recent dividend was $0.90 per share, based on a share price of $145.60. It was a payout ratio of 61.39% compared to their total earnings.

Sentiment

BSX

"Sentiment" not found for BSX

JNJ
72/100

JNJ had a bullish sentiment score of 71.87% across Twitter and StockTwits over the last 12 months. It had an average of 205.31 posts, 3,341.61 comments, and 16,552.61 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Boston Scientific Corp. Summary

New York Stock Exchange / BSX
Healthcare
Medical - Devices
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Johnson & Johnson Summary

New York Stock Exchange / JNJ
Healthcare
Drug Manufacturers - General
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.